Abstract
Herein, we present an overview of the historic development of drugs for the treatment of Parkinson’s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson's disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson’s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.
Keywords: Adenosine A2A receptor antagonist, bivalent ligand, dopamine, dopamine D2 receptor agonist, G protein-coupled receptor, levodopa, non-dopaminergic drug, Parkinson’s disease.
Current Medicinal Chemistry
Title:The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease
Volume: 21 Issue: 27
Author(s): M. Jorg, P.J. Scammells and B. Capuano
Affiliation:
Keywords: Adenosine A2A receptor antagonist, bivalent ligand, dopamine, dopamine D2 receptor agonist, G protein-coupled receptor, levodopa, non-dopaminergic drug, Parkinson’s disease.
Abstract: Herein, we present an overview of the historic development of drugs for the treatment of Parkinson’s disease as well as prospective novel treatment forms based on targeting the dopamine and adenosine receptors. The review includes the development of levodopa, a precursor of the neurotransmitter dopamine, which to date is the most commonly prescribed and most effective drug for controlling the motor symptoms of Parkinson's disease, to more recent studies of the adenosine receptor; a promising target for the treatment of Parkinson’s disease due to its intrinsic neuroprotective nature. Ongoing and future drug-based research on the dopamine and adenosine receptors has the advantage of being guided by the improved understanding of receptor topography as well as their functional roles. Breakthroughs such as the first ligand-bound X-ray structure of a selective adenosine A2A receptor antagonist in complex with the adenosine A2A receptor, the discovery of the existence of dopamine D2 homodimers, dopamine D2- adenosine A2A heterodimers and higher order oligomers in addition to technological progress have changed the direction of research in academia and industry and form the pillars for novel and exciting discoveries in this field.
Export Options
About this article
Cite this article as:
Jorg M., Scammells P.J. and Capuano B., The Dopamine D2 and Adenosine A2A Receptors: Past, Present and Future Trends for the Treatment of Parkinson's Disease, Current Medicinal Chemistry 2014; 21 (27) . https://dx.doi.org/10.2174/1389200215666140217110716
DOI https://dx.doi.org/10.2174/1389200215666140217110716 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of a High Throughput Drug Screening Assay for the Detection of Changes in Tau Levels - Proof of Concept with HSP90 inhibitors
Current Alzheimer Research Animal Models of Maternal Immune Activation in Depression Research
Current Neuropharmacology Healthcare Utilization, Unmet Service Needs, and Medication Adherence Among People Living with HIV/AIDS
Current HIV Research Cyclooxygenase-2 Biology
Current Pharmaceutical Design Nociceptinergic System as Potential Target in Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry MIANN Models in Medicinal, Physical and Organic Chemistry
Current Topics in Medicinal Chemistry Insulin and Endothelial Function: Physiological Environment Defines Effect on Atherosclerotic Risk
Current Diabetes Reviews Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Oxidative Stress and Accelerated Aging in Neurodegenerative and Neuropsychiatric Disorder
Current Pharmaceutical Design Antidepressant Use in Children and Adolescents Diagnosed with Major Depressive Disorder: What Can We Learn from Published Data?
Reviews on Recent Clinical Trials Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry MicroRNAs in Glioblastoma: Role in Pathogenesis and Opportunities for Targeted Therapies
CNS & Neurological Disorders - Drug Targets Neurochemical Changes in the Brain After Fetal Exposure to Fluoxetine, A Serotonin Reuptake Inhibitor (SRI) in Rodents
Current Proteomics Plasma Level of D-dimer is an Independent Diagnostic Biomarker for Deep Venous Thrombosis in Patients with Ischemic Stroke
Current Neurovascular Research The Cholesterol Transport Inhibitor U18666a Regulates Amyloid Precursor Protein Metabolism and Trafficking in N2aAPP “Swedish” Cells
Current Alzheimer Research Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Synthesis of piperidine-4-one Derivative Containing Dipeptide: An Acetyl cholinesterase and β-secretase Inhibitor
Anti-Infective Agents Preface (Nicholas D. P. Cosford)
Current Drug Targets - CNS & Neurological Disorders Cyanopeptides: A New and Nearly Inexhaustible Natural Resource for the Design and Structure-Activity Relationship Studies of New Inhibitors of Trypsin-like Serine Proteases
Current Enzyme Inhibition EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research